



New Jersey Medical School

Global Tuberculosis Institute

TRI-STATE TB INTENSIVE WORKSHOP

SEPTEMBER 25-27, 2018
CME/CNE CERTIFIED ACTIVITY

Course Location

Ohio Department of Transportation
1980 West Broad Street
Columbus, OH 43223

Jointly Provided By

Global Tuberculosis Institute at Rutgers, The State University of New Jersey, Indiana State Department of Health, Michigan Department of Health and Human Services, and Ohio Department of Health

WHY COURSE IS NEEDED

As the incidence of tuberculosis continues to decline, maintaining clinical and public health expertise in TB is particularly challenging. Therefore, ongoing training and education are important for healthcare providers to enhance skills in TB diagnosis, follow recommended treatment guidelines, and interact effectively with public health agencies. This type of training is also important for new clinicians working in TB control or other settings.

COURSE DESCRIPTION & OVERALL GOAL

This workshop for clinicians provides comprehensive information on the application of principles for the diagnosis and treatment of TB, as well as the management of TB in special populations. Topics include transmission and pathogenesis, diagnosis and treatment, drug resistance, extra-pulmonary TB, TB and diabetes, and key aspects of patient management. The format includes lectures, interactive discussions, and case studies.

COURSE REQUIREMENTS

This course will build upon basic TB concepts. Prior to the course, it is recommended that participants review the CDC's *Core Curriculum on Tuberculosis: What the Clinician Should Know* (Available at: <http://www.cdc.gov/tb/education/corecurr/default.htm>). In order to meet the learning objectives and receive continuing education credits, participants are required to attend the entire course, and complete an evaluation form. A post-course follow-up evaluation will be sent within 6 months of the course.

WHO SHOULD ATTEND

The workshop is designed for physicians, nurses and healthcare professionals who are involved in the diagnosis and management of TB patients. Individuals who work in the following settings would benefit from attending this workshop:

- TB Programs
- Health Departments
- Hospital Infection Control
- Correctional Facilities
- Long Term Care Facilities
- Immigrant & Refugee Health
- Community Health Settings
- College or University Health Services

OBJECTIVES

Upon completion of this workshop, participants should be better able to:

- Apply the latest advances for assessing risk, testing, and treating TB infection to prevent the development of disease.
- Interpret epidemiologic trends to better screen and treat groups who are at high risk for tuberculosis.
- Implement recommendations for prompt diagnosis, appropriate treatment and effective management of tuberculosis disease.
- List approaches for addressing clinical and social challenges in the management of patients with tuberculosis to achieve successful outcomes.
- Develop strategies for the care of TB patients with co-morbidities to ensure prompt diagnosis, integrated treatment, and effective management.

FACULTY LIST

Charlie Bark, MD

Medical Director, Cuyahoga County Tuberculosis Clinic
MetroHealth Medical Center, Division of Infectious Diseases

Premal Bhatt, MPH

Epidemiology Investigator 2, TB Program
Ohio Department of Health, Bureau of Infectious Diseases

Lisa Haglund, MD

Assistant Professor of Clinical Medicine, Division of Infectious Diseases
University of Cincinnati

Thomas Herchline, MD

Medical Director
Dayton and Montgomery County TB Clinic

Kimatha Hurst, RN, BSN

Public Health Nurse
Summit County Public Health

April Justice, RN

Infectious Disease Control Consultant
Ohio Department of Health

Dana Kissner, MD

Medical Director, TB Clinical Services
Detroit Department of Health and Wellness Promotion

Karthik Kondapally, MPH

Epidemiologist, TB Program
Ohio Department of Health, Bureau of Infectious Diseases

Rebecca Kramer

Microbiologist, Mycobacteriology/Mycology Unit, Bureau of Labs
Michigan Department of Health and Human Services

Trini Mathew, MD, MPH, FACP, FIDSA

Medical Director of Hospital Epidemiology and Infection Control
Beaumont Hospital-Royal Oak

Angie Schooley

Mycobacteriology/Mycology Unit Manager, Bureau of Labs
Michigan Department of Health and Human Services

Gloria Smith, RN, CLC

Nursing Supervisor, Nursing Division
Clark County Combined Health District

James Sunstrum, MD

TB Clinic Director
Wayne County Health Department

Sarah Tapyrik, MD, FCCP

Assistant Director, Pulmonary and Critical Care Medicine Fellowship
The Ohio State University, Wexner Medical Center

PLANNING COMMITTEE

Global Tuberculosis Institute

Anita Khilall, MPH - Director of Education & Training
Alfred Lardizabal, MD - Executive Director
Amy Lewis, MPH, MCHES - Health Educator

Indiana State Department of Health

Kelly White, MPH - Director, TB/Refugee Health

Michigan Department of Health and Human Services

Peter Davidson, PhD - TB Program Manager
Helen McGuirk, MPH - TB Public Health Consultant
Shona Smith, MPH - TB Epidemiologist, Communicable Disease Division

Ohio Department of Health

April Justice, RN - Infectious Disease Control Consultant
Sarah Mitchell, MS, LNHA - Supervisor, Tuberculosis, Antimicrobial Stewardship and Healthcare-Associated Infectious Program, TB Controller, Bureau of Infectious Diseases

AGENDA

Tuesday, September 25, 2018

8:30 am Registration / Breakfast
9:00 am Welcome & Course Overview
9:15 am Diagnosis of TB Infection
10:15 am Break
10:30 am Discussion: Use of TST vs. IGRA
11:00 am Treatment of TB Infection
12:00 pm Lunch
1:00 pm Approaches for Patient Education
1:30 pm Strategies for Improving Treatment Completion
2:15 pm Break
2:30 pm B1, B2, B Ready
3:15 pm Case Studies
4:00 pm Adjourn

Wednesday, September 26, 2018

8:30 am Sign-in / Breakfast
9:00 am Epidemiology of TB
9:45 am Transmission & Pathogenesis of TB
10:45 am Break

11:00 am Interpretation of Chest Radiographs
12:00 pm Lunch
1:00 pm Laboratory Methods for Diagnosis of TB Disease
2:00 pm Treatment of Tuberculosis Disease
3:00 pm Break
3:15 pm Managing Adverse Drug Reactions
4:15 pm Adjourn

Thursday, September 27, 2018

8:30 am Sign-in / Breakfast
9:00 am Extra-pulmonary Tuberculosis
10:00 am Break
10:15 am Management of Drug Resistant TB
11:15 am Role of TB Nurse Case Management
12:00 pm Lunch
1:00 pm TB and Alcohol Use Disorders
2:00 pm Break
2:15 pm TB and Diabetes
3:15 pm Ask the Expert
4:00 pm Evaluation & Wrap-up
4:30 pm Adjourn

CONTINUING EDUCATION INFORMATION



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences, Indiana State Department of Health, Michigan Department of Health and Human Services and Ohio Department of Health. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 17.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: This activity is awarded 17.25 contact hours (60-minute CH). Nurses should only claim those contact hours actually spent participating in the activity.

PEER REVIEW STATEMENT

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Biomedical and Health Sciences (RBHS) has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers. This activity has been peer reviewed for relevance, accuracy of content and balance of presentation by Amy Lewis, MPH, MCHES and Anita Khilall, MPH.

DISCLOSURE DISCLAIMER

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Financial Disclosure

The following faculty and planning committee members have stated that they have no relevant financial relationships to disclose:

Charlie Bark, MD
Premal Bhatt, MPH
Peter Davidson, PhD
Lisa Haglund, MD
Thomas Herchline, MD
Kimatha Hurst, RN, BSN
April Justice, RN
Anita Khilall, MPH
Dana Kissner, MD
Karthik Kondapally, MPH
Rebecca Kramer
Alfred Lardizabal, MD
Amy Lewis, MPH, MCHES
Trini Mathew, MD, MPH, FACP, FIDSA
Helen McGuirk, MPH
Sarah Mitchell, MS, LNHA
Angie Schooley
Gloria Smith, RN, CLC

Shona Smith, MPH
James Sunstrum, MD
Sarah Tapyrik, MD, FCCP
Kelly White, MPH

RBHS Center for Continuing and Outreach Education Staff
Elizabeth Ward, MSJ, Executive Director has no relevant financial relationships to disclose.

Off-Label/Investigational Use Disclosure

The course will include the off-label discussion of Levofloxacin, Moxifloxacin, Rifabutin, Amikacin, Kanamycin, Linezolid, Clofazimine. Off-label indication is treatment of multidrug TB or TB with drug intolerances/allergies.

CONTENT DISCLAIMER

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, or Rutgers. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data or procedures before using them in clinical practice. Rutgers reserves the right to modify the activity content and faculty if necessary.

COPYRIGHT

Copyright©2018 Rutgers, The State University of New Jersey. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers.

Please direct continuing education related questions to CCOE at 973-972-4267 or email ccoe@ca.rutgers.edu.

Please direct content or course related questions to Amy Lewis 973-972-0978 or email lewisa1@rutgers.edu.

FUNDING DISCLOSURE

Funding for this course was made possible in part by the Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. government.